The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Astellas, Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through educational grants from Bristol Myers Squibb and the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View aml content recommended for you
#EHA2024: Late-phase trials in AML
To update you on the exciting content presented at the European Hematology Association (EHA) 2024 Hybrid Congress, we have collated our social media coverage. Catch up here with our live social media relating to late-phase trials in acute myeloid leukemia (AML).
CONGRESS | #EHA2024
— AML Hub (@AML_Hub) June 15, 2024
In the plenary abstracts session, Uwe Platzbecker @UwePlatzbecker @UniLeipzig presents the first results from the open-label randomized phase III APOLLO trial of ATO with ATRA and Ida vs standard ATRA plus chemotherapy regimen in 131 patients with ND HR #APL.… pic.twitter.com/uwp7y5ngi3
CONGRESS | #EHA2024
— AML Hub (@AML_Hub) June 15, 2024
Maria Teresa Voso @unitorvergata presents a post-hoc analysis of patients with AML-MRC who received oral azacitidine (n=56) vs placebo (n=45) maintenance in the QUAZAR AML-001 trial.
▪️ Oral Aza improved OS (19.9 months vs 14.8 months), RFS (7.5 months vs 3.7… pic.twitter.com/ixHcjYBnZQ
CONGRESS | #EHA2024
— AML Hub (@AML_Hub) June 15, 2024
Mikkael A. Sekeres @MikkaelSekeres @SylvesterCancer @UMiamiHealth discusses an exploratory analysis of continuation therapy impact on quizartinib efficacy in patients with ND FLT3m AML in the phase III QuANTUM-First trial.
▪️ In patients who received… pic.twitter.com/xJ1Li2Y0Yr
CONGRESS #EHA2024 | Andrius Žučenka @zucenka @VU_LT reports efficacy and safety of the quadruplet G-ACTIVE (gilteritinib+actinomycin D+cytarabine+venetoclax) salvage treatment in pts with FLT3m R/R AML (N=25). Among 16 pts meeting the inclusion criteria of the phase III ADMIRAL… pic.twitter.com/MwJgfyue48
— AML Hub (@AML_Hub) June 16, 2024
CONGRESS | #EHA2024 | Poster
— AML Hub (@AML_Hub) June 18, 2024
James Foran @MayoClinic presents long-term data from the phase III SIERRA trial of 131I-apamstamab (Iomab-B, an anti-CD45 radioimmuoconjugate)-led HSCT vs conventional care in older patients with R/R AML.
▪️ Primary endpoint was met: dCR = 22% vs 0%… pic.twitter.com/zDSQ4VYkFb
CONGRESS #EHA2024 | Naval Daver @Daver_Leukemia @MDAndersonNews presents findings of the phase III ENHANCE-3 study (NCT05079230) evaluating efficacy and safety of magrolimab (vs placebo) in combination with azacitidine and venetoclax in pts with previously untreated AML… pic.twitter.com/4xDfR7XLjG
— AML Hub (@AML_Hub) June 15, 2024
CONGRESS #EHA2024 | Andrew Wei @PeterMacCC shares outcomes from the QUAZAR AML-001 trial, evaluating the impact of TP53 mutations on clinical response in 310 pts with AML during oral azacitidine maintenance therapy.
— AML Hub (@AML_Hub) June 15, 2024
▪️ Among 15% pts with TP53mut at BL, mRFS was 7.4 vs 3.5 months… pic.twitter.com/FHKtG5npVv
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
